Literature DB >> 1516262

Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).

H Ohi1, S Watanabe, T Fujita, T Yasugi.   

Abstract

C3NeF is an autoantibody of C3 convertase (C3bBb) and is often detected in the serum of hypocomplementaemic MPGN patients. Serum samples from 104 non-hypocomplementaemic MPGN patients (C3NeF) were studied. C3NeF, which cannot activate the alternative pathway, was found in the sera of 6 patients. We examined the C3NeF in purified IgG from five of the non-hypocomplementaemic serum samples (non-hypo C3NeF) and four hypocomplementaemic serum samples (hypocomplementaemic C3NeF) to determine why C3NeF does not induce C3 splitting and hypocomplementaemia. Purified IgG from non-hypo C3NeF stabilized EAC4b3bBb cells in a manner similar to IgG from hypocomplementaemic C3NeF in EDTA gelatin veronal buffer. However, the non-hypo C3NeF IgG did not stabilize C3 convertase (EAC4b3bBb cells) in the presence of control proteins (factors H and I), whereas the hypocomplementaemic C3NeF IgG did. The C3NeF in the hypocomplementaemic serum displayed two characteristics: (i) inhibition of intrinsic decay of Ce convertase (C3bBb); and (ii) inhibition of extrinsic decay by factors H and I. Although the C3NeF in the non-hypocomplementaemic sera did inhibit the intrinsic decay in a manner similar to the hypocomplementaemic C3NeF IgG, it did not inhibit the extrinsic decay. Due to the different characteristics of hypocomplementaemic C3NeF and non-hypo C3NeF in the serum samples, the non-hypo C3NeF did not activate C3. Therefore, we conclude that C3NeF exhibits a heterogeneity which is very important in relation to the pathogenesis of MPGN.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516262      PMCID: PMC1554488          DOI: 10.1111/j.1365-2249.1992.tb06984.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  The immunogloblin nature of nephritic factor (NeF).

Authors:  D M Scott; N Amos; J G Sissons; P J Lachmann; D K Peters
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

2.  Is membranoproliferative glomerulonephritis an autoimmune disease?

Authors:  H Ohi; Y Tanuma; M Hatano
Journal:  Nephron       Date:  1990       Impact factor: 2.847

3.  A new method for the preparation of EAC14 cell with human or guinea-pig serum.

Authors:  K Nagaki; K Iida; S Inai
Journal:  J Immunol Methods       Date:  1974-08       Impact factor: 2.303

4.  Serum C'3 lytic system in patients with glomerulonephritis.

Authors:  R E Spitzer; E H Vallota; J Forristal; E Sudora; A Stitzel; N C Davis; C D West
Journal:  Science       Date:  1969-04-25       Impact factor: 47.728

5.  C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.

Authors:  Y Tanuma; H Ohi; S Watanabe; M Seki; M Hatano
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

6.  Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis.

Authors:  H Ohi; S Watanabe; T Fujita; M Seki; M Hatano
Journal:  J Immunol Methods       Date:  1990-07-20       Impact factor: 2.303

7.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

8.  Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma.

Authors:  I Brandslund; H C Siersted; S E Svehag; B Teisner
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

9.  Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event.

Authors:  R E Spitzer; A E Stitzel; G C Tsokos
Journal:  J Pediatr       Date:  1990-05       Impact factor: 4.406

10.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

View more
  9 in total

1.  Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Authors:  Valérie Leroy; Véronique Fremeaux-Bacchi; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes; Marie-Alice Macher; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2010-12-25       Impact factor: 3.714

Review 2.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

3.  C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.

Authors:  Allison Lesher Williams; Damodar Gullipalli; Yoshiyasu Ueda; Sayaka Sato; Lin Zhou; Takashi Miwa; Kenneth S Tung; Wen-Chao Song
Journal:  Kidney Int       Date:  2017-01-27       Impact factor: 10.612

Review 4.  The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.

Authors:  Federica Defendi; Nicole M Thielens; Giovanna Clavarino; Jean-Yves Cesbron; Chantal Dumestre-Pérard
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

Review 5.  Complement components and their autoantibodies.

Authors:  P Norsworthy; K A Davies
Journal:  Mol Biotechnol       Date:  2003-03       Impact factor: 2.860

6.  Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.

Authors:  Marloes A H M Michels; Nicole C A J van de Kar; Marcin Okrój; Anna M Blom; Sanne A W van Kraaij; Elena B Volokhina; Lambertus P W J van den Heuvel
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

7.  Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.

Authors:  Marloes A H M Michels; Nicole C A J van de Kar; Ramon M van den Bos; Thea J A M van der Velden; Sanne A W van Kraaij; Sebastian A Sarlea; Valentina Gracchi; Michiel J S Oosterveld; Elena B Volokhina; Lambertus P W J van den Heuvel
Journal:  Front Immunol       Date:  2019-06-17       Impact factor: 7.561

8.  Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.

Authors:  Danielle Paixão-Cavalcante; Margarita López-Trascasa; Lillemor Skattum; Patricia C Giclas; Timothy H Goodship; Santiago Rodríguez de Córdoba; Lennart Truedsson; B Paul Morgan; Claire L Harris
Journal:  Kidney Int       Date:  2012-08-01       Impact factor: 10.612

9.  Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.

Authors:  Roberta Donadelli; Patrizia Pulieri; Rossella Piras; Paraskevas Iatropoulos; Elisabetta Valoti; Ariela Benigni; Giuseppe Remuzzi; Marina Noris
Journal:  Front Immunol       Date:  2018-10-15       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.